Obesity and skin and soft tissue infections: How to optimize antimicrobial usage for prevention and treatment?

Current Opinion in Infectious Diseases

Volumn 30, Issue 2, 2017, Pages 180-191

  Grupper, Mordechai ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

Antimicrobials; Obesity; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ANTIINFECTIVE AGENT; CEFAZOLIN; CEFTAROLINE; DALBAVANCIN; DAPTOMYCIN; LINEZOLID; TEDIZOLID; TEICOPLANIN; TELAVANCIN; TIGECYCLINE; VANCOMYCIN;

ANTIMICROBIAL THERAPY; CLINICAL TRIAL (TOPIC); DRUG USE; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; OBESITY; REVIEW; SKIN INFECTION; SOFT TISSUE INFECTION; SYSTEMATIC REVIEW (TOPIC); BACTERIAL SKIN DISEASE; COMPLICATION; METABOLISM; STAPHYLOCOCCAL SKIN INFECTION;

ANTI-BACTERIAL AGENTS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; OBESITY; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL SKIN INFECTIONS;

EID: 85010874997     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000356     Document Type: Review

References (74)

1. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis 2014; 59: 147-159.
2. http://www.euro.who.int/en/health-Topics/noncommunicable-diseases/obesity/data-And-statistics. Accessed 25 May 2016.
3. Halilovic J, Heintz BH, Brown J. Risk factors for clinical failure in patients hospitalized with cellulitis and cutaneous abscess. J Infect 2012; 65: 128-134.
4. Khawcharoenporn T, Tice AD, Grandinetti A, et al. Risk factors for communityassociated methicillin-resistant Staphylococcus aureus cellulites-And the value of recognition. Hawaii Med J 2010; 69: 232-236.
5. Falagas ME, Karageorgopoulos DE. Adjustment of dosing of antimicrobial agents for bodyweight in adults. Lancet 2010; 375: 248-251.
6. Pai MP. Treatment of bacterial infections in obese adult patients: How to appropriately manage antimicrobial dosage. Curr Opin Pharmacol 2015; 24: 12-17.
7. Payne KD, Hall RG 2nd. Dosing of antibacterial agents in obese adults: Does one size fit all? Expert Rev Anti Infect Ther 2014; 12: 829-854.
8. Pea F. Practical concept of pharmacokinetics/pharmacodynamics in the management of skin and soft tissue infections. Curr Opin Infect Dis 2016; 29: 153-159.
9. Fischer MI, Dias C, Stein A, et al. Antibiotic prophylaxis in obese patients submitted to bariatric surgery. A systematic review. Acta Cir Bras 2014; 29: 209-217.
10. Bratzler DW, Dellinger EP, Olsen KM, et al., American Society of Health-System Pharmacists; Infectious Disease Society of America; Surgical Infection Society; Society for Healthcare Epidemiology of America. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm 2013; 70: 195-283.
11. Pevzner L, Swank M, Krepel C, et al. Effects of maternal obesity on tissue concentrations of prophylactic cefazolin during cesarean delivery. Obstet Gynecol 2011; 117: 877-882.
12. Stitely M, Sweet M, Slain D, et al. Plasma and tissue cefazolin concentrations in obese patients undergoing cesarean delivery and receiving differing preoperative doses of drug. Surg Infect (Larchmt) 2013; 14: 455-459.
13. Swank ML, Wing DA, Nicolau DP, et al. Increased 3-gram cefazolin dosing for cesarean delivery prophylaxis in obese women. Am J Obstet Gynecol 2015; 213: 415.
14. Maggio L, Nicolau DP, DaCosta M, et al. Cefazolin prophylaxis in obese women undergoing cesarean delivery: A randomized controlled trial. Obstet Gynecol 2015; 125: 1205-1210.
15. Young OM, Shaik IH, Twedt R, et al. Pharmacokinetics of cefazolin prophylaxis in obese gravidae at time of cesarean delivery. Am J Obstet Gynecol 2015; 213: 541.
16. Grupper M, Kuti JL, Swank ML, et al. Population pharmacokinetics of cefazolin in serum and adipose tissue from overweight and obese women undergoing cesarean delivery. J Clin Pharmacol 2016; Doi: 10.1002/jcph.851. [Epub ahead of print]
17. van Kralingen S, Taks M, Diepstraten J, et al. Pharmacokinetics and protein binding of cefazolin in morbidly obese patients. Eur J Clin Pharmacol 2011; 67: 985-992.
18. Ho VP, Nicolau DP, Dakin GF, et al. Cefazolin dosing for surgical prophylaxis in morbidly obese patients. Surg Infect (Larchmt) 2012; 13: 33-37.
19. Brill MJ, Houwink AP, Schmidt S, et al. Reduced subcutaneous tissue distribution of cefazolin in morbidly obese versus nonobese patients determined using clinical microdialysis. J Antimicrob Chemother 2014; 69: 715-723.
20. Anlicoara R, Ferraz ÁA, da P, et al. Antibiotic prophylaxis in bariatric surgery with continuous infusion of cefazolin: Determination of concentration in adipose tissue. Obes Surg 2014; 24: 1487-1491.
21. So W, Kuti JL, Nicolau DP. Population pharmacokinetics of cefazolin in serum and tissue for patients with complicated skin and soft tissue infections (cSSTI). Infect Dis Ther 2014; 3: 269-279.
22. Peppard WJ, Eberle DG, Kugler NW, et al. Association between pre-operative cefazolin dose and surgical site infection in obese patients. Surg Infect (Larchmt) 2016. [Epub ahead of print]
23. Alobaid AS, Hites M, Lipman J, et al. Effect of obesity on the pharmacokinetics of antimicrobials in critically ill patients: A structured review. Int J Antimicrob Agents 2016; 47: 259-268.
24. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009; 66: 82-98.
25. Liu C, Bayer A, Cosgrove SE, et al. Infectious Diseases Society of America. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52: E18-e55.
26. http://www.medicines.org.uk/emc/medicine/27321#companyDetails. Accessed 26 April 2016.
27. Matsumoto K, Watanabe E, Kanazawa N, et al. Pharmacokinetic/pharmacodynamic analysis of teicoplanin in patients with MRSA infections. Clin Pharmacol 2016; 8: 15-18.
28. http://www.accessdata.fda.gov/drugsatfda-docs/label/2008/021130s016,021131s013,021132s014lbl.pdf. Accessed 25 May 2016.
29. Canut A, Isla A, Betriu C, et al. Pharmacokinetic-pharmacodynamic evaluation of daptomycin, tigecycline, and linezolid versus vancomycin for the treatment of MRSA infections in four western European countries. Eur J Clin Microbiol Infect Dis 2012; 31: 2227-2235.
30. https://www.merck.com/product/usa/pi-circulars/s/sivextro/sivextro-pi.pdf. Accessed 25 May 2016.
31. Lodise TP, Drusano GL. Use of pharmacokinetic/pharmacodynamic systems analyses to inform dose selection of tedizolid phosphate. Clin Infect Dis 2014; 58 (Suppl 1): S28-S34.
32. http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/021821s026 s031lbl.pdf. Accessed 25 May 2016.
33. http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/021572s038lbl.pdf. Accessed 25 May 2016.
34. Safdar N, Andes D, Craig WA. In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother 2004; 48: 63-68.
35. http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/200327s000lbl.pdf. Accessed 25 May 2016.
36. Merker A, Danziger LH, Rodvold KA, et al. Pharmacokinetic and pharmacodynamic evaluation of ceftaroline fosamil. Expert Opin Drug Metab Toxicol 2014; 10: 1741-1750.
37. Bassetti M, Righi E, Carnelutti A. New therapeutic options for skin and soft tissue infections. Curr Opin Infect Dis 2016; 29: 99-108.
38. http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/022110s000lbl.pdf. Accessed 25 May 2016.
39. Lodise TP, Butterfield JM, Hegde SS, et al. Telavancin pharmacokinetics and pharmacodynamics in patients with complicated skin and skin structure infections and various degrees of renal function. Antimicrob Agents Chemother 2012; 56: 2062-2066.
40. http://www.allergan.com/assets/pdf/dalvance-pi. Accessed 25 May 2016.
41. Andes D, Craig WA. In vivo pharmacodynamic activity of the glycopeptide dalbavancin. Antimicrob Agents Chemother 2007; 51: 1633-1642.
42. http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/022110s000lbl.pdf. Accessed 25 May 2016.
43. Brade KD, Rybak JM, Rybak MJ. Oritavancin: A new lipoglycopeptide antibiotic in the treatment of Gram-positive infections. Infect Dis Ther 2016; 5: 1-15.
44. Grace E. Altered vancomycin pharmacokinetics in obese and morbidly obese patients: What we have learned over the past 30 years. J Antimicrob Chemother 2012; 67: 1305-1310.
45. Adane ED, Herald M, Koura F. Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections. Pharmacotherapy 2015; 35: 127-139.
46. Hamada Y, Kuti JL, Nicolau DP. Vancomycin serum concentrations do not adequately predict tissue exposure in diabetic patients with mild to moderate limb infections. J Antimicrob Chemother 2015; 70: 2064-2067.
47. Hamada Y, Kuti JL, Nicolau DP. In vitro pharmacodynamics of vancomycin against methicillin-susceptible and -resistant Staphylococcus aureus: Considering the variability in observed tissue exposure. Antimicrob Agents Chemother 2015; 60: 955-961.
48. Stein GE, Wells EM. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-Tissue infections caused by methicillin-resistant Staphylococcus aureus: Vancomycin and linezolid. Curr Med Res Opin 2010; 26: 571-588.
49. Lawson W, Nathwani D, Eckmann C, et al. Weight-based antibiotic dosing in a real-world European study of complicated skin and soft-Tissue infections due to methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect 2015; 21 (Suppl 2): S40-S46.
50. Soy D, López E, Ribas J. Teicoplanin population pharmacokinetic analysis in hospitalized patients. Ther Drug Monit 2006; 28: 737-743.
51. Bhalodi AA, Papasavas PK, Tishler DS, et al. Pharmacokinetics of intravenous linezolid in moderately to morbidly obese adults. Antimicrob Agents Chemother 2013; 57: 1144-1149.
52. Puzniak LA, Morrow LE, Huang DB, et al. Impact of weight on treatment efficacy and safety in complicated skin and skin structure infections and nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Ther 2013; 35: 1557-1570.
53. Flanagan S, Passarell J, Lu Q, et al. Tedizolid population pharmacokinetics, exposure response, and target attainment. Antimicrob Agents Chemother 2014; 58: 6462-6470.
54. Sahre M, Sabarinath S, Grant M, et al. Skin and soft tissue concentrations of tedizolid (formerly torezolid), a novel oxazolidinone, following a single oral dose in healthy volunteers. Int J Antimicrob Agents 2012; 40: 51-54.
55. Rubino CM, Bhavnani SM, Forrest A, et al. Pharmacokinetics-pharmacodynamics of tigecycline in patients with community-Acquired pneumonia. Antimicrob Agents Chemother 2012; 56: 130-136.
56. Van Wart SA, Owen JS, Ludwig EA, et al. Population pharmacokinetics of tigecycline in patients with complicated intra-Abdominal or skin and skin structure infections. Antimicrob Agents Chemother 2006; 50: 3701-3707.
57. Van Wart SA, Cirincione BB, Ludwig EA, et al. Population pharmacokinetics of tigecycline in healthy volunteers. J Clin Pharmacol 2007; 47: 727-737.
58. Pai MP. Serum and urine pharmacokinetics of tigecycline in obese class III and normal weight adults. J Antimicrob Chemother 2014; 69: 190-199.
59. Bulik CC, Wiskirchen DE, Shepard A, et al. Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis. Antimicrob Agents Chemother 2010; 54: 5209-5213.
60. Meagher AK, Passarell JA, Cirincione BB, et al. Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections. Antimicrob Agents Chemother 2007; 51: 1939-1945.
61. Polso AK, Lassiter JL, Nagel JL. Impact of hospital guideline for weight-based antimicrobial dosing in morbidly obese adults and comprehensive literature review. J Clin Pharm Ther 2014; 39: 584-608.
62. Kim A, Suecof LA, Sutherland CA, et al. In vivo microdialysis study of the penetration of daptomycin into soft tissues in diabetic versus healthy volunteers. Antimicrob Agents Chemother 2008; 52: 3941-3946.
63. Traunmüller F, Schintler MV, Metzler J, et al. Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections. J Antimicrob Chemother 2010; 65: 1252-1257.
64. Matzneller P, Lackner E, Lagler H, et al. Single-And repeated-dose pharmacokinetics of ceftaroline in plasma and soft tissues of healthy volunteers for two different dosing regimens of ceftaroline fosamil. Antimicrob Agents Chemother 2016; 60: 3617-3625.
65. Evans JD, Udeani G, Cole P, et al. Ceftaroline fosamil for the treatment of acute bacterial skin and skin structure infections in obese patients. Postgrad Med 2014; 126: 128-134.
66. Stryjewski ME, Graham DR, Wilson SE, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis 2008; 46: 1683-1693.
67. Samara E, Shaw JP, Barriere SL, et al. Population pharmacokinetics of telavancin in healthy subjects and patients with infections. Antimicrob Agents Chemother 2012; 56: 2067-2073.
68. Sun HK, Duchin K, Nightingale CH, et al. Tissue penetration of telavancin after intravenous administration in healthy subjects. Antimicrob Agents Chemother 2006; 50: 788-790.
69. Nicolau DP, Sun HK, Seltzer E, et al. Pharmacokinetics of dalbavancin in plasma and skin blister fluid. J Antimicrob Chemother 2007; 60: 681-684.
70. Dunne MW, Puttagunta S, Sprenger CR, et al. Extended-duration dosing and distribution of dalbavancin into bone and articular tissue. Antimicrob Agents Chemother 2015; 59: 1849-1855.
71. Corey GR, Kabler H, Mehra P, et al. SOLO I Investigators. Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med 2014; 370: 2180-2190.
72. Corey GR, Good S, Jiang H, et al. SOLO II Investigators. Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: The SOLO II noninferiority study. Clin Infect Dis 2015; 60: 254-262.
73. RubinoCM, Bhavnani SM, Moeck G, et al. Population pharmacokinetic analysis for a single 1,200-milligram dose of oritavancin using data from two pivotal phase 3 clinical trials. Antimicrob Agents Chemother 2015; 59: 3365-3372.
74. Fetterly GJ, Ong CM, Bhavnani SM, et al. Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose. Antimicrob Agents Chemother 2005; 49: 148-152.